Background. Hepatitis B vaccine is an effective measure to prevent hepatitis B virus infection. Whether chronic hepatitis C virus (HCV) infection decreases humoral and cell-mediated immunity responses to hepatitis B vaccination is still controversial.
Both hepatitis B virus (HBV) and hepatitis C virus (HCV) can cause chronic liver disease and hepatocellular carcinoma [1, 2] . Because they share common modes of transmission, coinfection is a fairly frequent occurrence, especially in highly endemic areas and among subjects with a high risk of parenteral infections [3] [4] [5] . The estimated prevalence of HBV-HCV coinfection varies greatly in different areas and is approximately 5%-20% in patients positive for hepatitis B surface antigen (HBsAg) and 2%-10% in HCV-positive patients [6] . Although HBV infection could lower the replication of HCV [7] , HBV-HCV coinfection can enhance the severity of hepatitis and the risks of liver cirrhosis and hepatocellular carcinoma [8, 9] .
It is well documented that HBV infection can be effectively prevented by hepatitis B vaccination, although no hepatitis C vaccine is yet available. Hepatitis B vaccination is regarded as a promising way to prevent the coinfection of HBV and HCV and is recommended for patients with chronic hepatitis C in some countries [10] [11] [12] . The immunogenicity and safety of hepatitis B vaccination among such patients has been studied, but the results were controversial, and the reported seroconversion rates of antibody to HBsAg (anti-HBs) varied from 56% to 91% [13] [14] [15] [16] . In addition, studies of cytokine response to hepatitis B vaccine among patients with chronic hepatitis C infection have seldom been reported.
Both HBV and HCV infection are major public health concerns in China. According to a national serosurvey in 2006, the prevalence rate of HBsAg was 7.18% in the general population [17] . Although the prevalence of HCV antibody (anti-HCV) is not high (0.43%) in China [18] , the absolute number of individuals with HCV infection is large because of the huge population in the country, and the number of hepatitis C cases reported to the National Notifiable Disease Reporting System of China has been increasing in recent years [19] . Although hepatitis B vaccine was recommended to patients with chronic liver diseases by the Chinese Center for Disease Control and Prevention in 2012 [20] , to our knowledge, no data were available about the immunogenicity and safety of hepatitis B vaccination in patients with chronic HCV infection in China.
We conducted this study, aiming to (1) compare the immunogenicity of hepatitis B vaccination in patients with chronic HCV infection and in healthy individuals, including antibody response and cell-mediated immunity (CMI); (2) explore potential factors associated with the antibody response in patients with chronic HCV infection; and (3) observe the safety of hepatitis B vaccination in patients with chronic HCV infection.
METHODS

Study Design and Participants
The study was conducted in 3 counties (Yucheng, Xintai, and Dongchangfu) of Shandong Province, China from 3 June 2013 to 26 January 2015. Potential patients with chronic HCV infection were recruited by checking the medical records of the hospitals or by inquiring of village physicians. Healthy individuals who did not have self-reported HCV infection were randomly selected by 3-5 times of potential patients with HCV infection in the same county. Questionnaire investigation was made and 10-mL blood samples were collected in the same way for each potential patient and healthy individual.
Inclusion criteria for HCV group were as follows: (1) age ≥22 years and Han nationality; (2) no history of hepatitis B vaccination; (3) not-in-treatment patients positive for anti-HCV and HCV RNA; (4) diagnosis of chronic hepatitis C based on self-reported history of HCV infection (>6 months) and screening tests for inclusion; and (5) negative results for HBsAg, anti-HBs, hepatitis B e antigen (HBeAg), antibody to HBeAg (anti-HBe), and antibody to hepatitis B core antigen (anti-HBc). Inclusion criteria for the healthy control group were as follows: (1) age ≥22 years and Han nationality; (2) no history of hepatitis B vaccination; (3) negative results for anti-HCV and HCV RNA; (4) negative results for HBsAg, anti-HBs, HBeAg, antiHBe, and anti-HBc; and (5) no self-reported acute or chronic diseases. The enrollment process ended after enrollment of 100 patients with HCV infection and 200 healthy individuals with patients matched 1:2 to controls by community, sex, and age (within 5 years) (Figure 1) .
The main exclusion criteria for all participants were (1) allergy to any vaccine component; (2) pregnancy or lactation; (3) axillary temperature ≥38°C in the past 3 days, acute disease in the past 7 days, or history of any vaccination in the past 4 weeks; (4) diseases that may influence immune function, such as severe cirrhosis with Child-Pugh score >5, renal failure, bleeding diathesis, malignant tumor, and HIV infection; (5) use of antiviral treatment in the past 5 days; and (6) chronic liver diseases, except those caused by HCV. Criteria for withdrawal from the vaccination protocol were (1) (2) alanine aminotransferase (ALT) level increasing >3-fold relative to an elevated baseline value or >6-fold relative to an upper limit of normal; (3) Child-Pugh score increasing by 2 points; and (4) anti-HBs level ≥100 mIU/mL at 1 month after the first dose of hepatitis B vaccination [21] . The study was approved by the institutional review board of Shandong Provincial Center for Disease Control and Prevention. Written informed consent was obtained from each participant before enrollment.
Questionnaire Survey
We performed a questionnaire-based survey to collect the base line information of the participants, including demographic information, medical history, and behavioral status.
Hepatitis B Vaccination and Follow-up
Three doses of hepatitis B vaccine, made in Saccharomyces cerevisiae using recombinant DNA techniques (HBsAg, 20 μg/1.0 mL per dose, with the adjuvant of aluminum hydroxide; Shenzhen Kangtai Biological Products) were given intramuscularly in the deltoid region to all participants at 0, 1, and 6 months. About 24 mL of blood with anticoagulant dipotassium ethylenediaminetetraacetic acid was collected for CMI assay before vaccination and 1 month after the third dose of vaccination. For the anti-HBs test, 5 mL was collected from each participant 1 month after the first and the third dose of vaccination.
Laboratory Assays and Physical Examination
HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, anti-HCV, and HCV RNA were assayed in all subjects at inclusion visits; serum bilirubin, serum albumin, prothrombin time, plasma ALT, and aspartate aminotransferase (AST) were measured in the HCV group. HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc were assayed using Abbott Chemiluminesent Microparticle ImmunoAssay (Abbott Ireland Diagnostics Division). Anti-HCV was measured by means of enzyme-linked immunosorbent assay with a commercial kit (Intec Products). HCV RNA was measured by means of quantitative real-time polymerase chain reaction with commercially available kits (Qiagen). Serum bilirubin, albumin, prothrombin time, plasma ALT, and AST levels were measured using standard reagent and methods. To assess disease activity, each patient with HCV infection underwent clinical examination, including interrogation, physical examination, and ultrasonography.
Anti-HBs Assay After Vaccination
Anti-HBs was detected using the Abbott Chemiluminesent Microparticle ImmunoAssay (Abbott Ireland Diagnostics Division) 1 month after the first and the third dose of vaccination. Although without serological HBV markers, subjects were defined as having a history of HBV infection or hepatitis B vaccination if anti-HBs was equal or greater than 100 mIU/ mL and anti-HBc was negative 1 month after the first dose of vaccination [21] .
CMI Assay
Before the first dose of vaccination, 50 subjects from the HCV group and 50 healthy controls were selected randomly to isolate peripheral blood mononuclear cells (PBMCs). One month after the third dose of vaccination, the selected subjects from both groups were used to isolate PBMCs again and test CMI function, using PBMCs isolated before the first dose and 1 month after the third dose of vaccination respectively, including interferon γ (IFN-γ) and interleukin 2, 4, 5, and 6 (IL-2, IL-4, IL-5, and IL-6). Hepatitis B surface antigen 28-39 polypeptide (S 28-39 ) polypeptide, major histocompatibility complex (MHC) class I polypeptide, MHC class II polypeptide, and HBsAg were used as cell immunologic stimulants for IFN-γ. HBsAg was used as a cell immunologic stimulant for IL-2, IL-4, IL-5, and IL-6. S 28-39 polypeptide and MHC I and II polypeptide mixtures were synthesized using amino acids manufactured by CSBio by Bo Mai Jie Technology. HBsAg was supplied by Shenzhen Kangtai Biological Products. After cryopreserved PBMCs were thawed and adjusted to the concentration of 2 × 10 6 /mL, 100 μL of PBMCs was added in the precoated polyvinylidene difluoride 96-well plates and 100 μL of S 28-39 peptide (IPQSLDSWWTSL; final concentration, 10 μg/ mL), MHC I polypeptide mixture, MHC II polypeptide mixture [22, 23] , or HBsAg (80 μg/mL) was added in each well. Plates were incubated at 37°C, in a humidified 5% carbon dioxide incubator for 20 (IFN-γ and IL-2) or 40 (IL-4, IL-5, and IL-6) hours. After incubation the plates were manipulated according to the R&D ELISPOT Kit (R&D Systems) instruction manual. Spot-forming cells (SFCs) were counted with an ImmunoSpot system (Cellular Technology).
Safety Assessment
Participants were provided with diary cards to record the occurrence and severity of solicited local reactions at the injection site (pain, induration, erythema, edema, and pruritus) for 7 days after vaccination and solicited systemic reactions (fever, headache, fatigue, cough, myalgia, asthenia, vertigo, and diarrhea) and any unsolicited adverse reactions for 29 days after vaccination.
Statistical Analyses
Individuals were considered nonresponders, low responders, normal responders, or high responders, respectively, with antiHBs levels of <10, 10 to <100, 100 to <1000, or ≥1000 mIU/mL [24] . Seroconversion was defined as anti-HBs levels ≥10 mIU/ mL. Body mass index (BMI) was stratified according to the recommendation of Cooperative Meta-analysis Group of China Obesity Task Force [25] : those with BMIs of18.5-23.9, 24-27.9, or ≥28 kg/m 2 were categorized as normal weight, overweight, and obese, respectively.
Data entry and database management were performed using EpiData 3.0 and Microsoft Excel 2010 software, respectively. Data analysis was performed with Stata 11.0 software. Differences between the HCV and healthy control groups in continuous and categorical variables were examined using conditioned logistic regression. Subgroups of nonresponders and low responders versus normal and high responders were evaluated in relation to demographic characteristics, biochemical indicators, liver disease status, and HCV RNA levels. Student t tests or 1-way analysis of variance were used to compare the average anti-HBs titers between different subgroups. Fisher exact test was used to compare the response rates. Nonparametric tests were used to compare SFC counts. Spearman rank correlation analysis was used to evaluate the correlation between SFC counts and antiHBs. For all of these comparisons, differences were considered statistically significant at P < .05 (2 sided)
RESULTS
Study Participants
Of the 100 triads of participants, 79 triads completed 3 doses of hepatitis B vaccination and were involved in the final analysis. Baseline characteristics were balanced between the 2 groups ( Table 1) . Sixty of 79 patients with chronic hepatitis C had a history of paid blood donation, which was considered the most possible transmission route for them.
Anti-HBs Analysis
One month after the third vaccine dose, the geometric mean concentration of anti-HBs was 810.21 mIU/mL (95% confidence interval, 623.73-1052.45 mIU/mL) in the HCV group and 559.85 mIU/mL (377.38-880.38 mIU/mL) in the healthy control group (P = .13). A response was observed in 76 patients (96.20%; 95% confidence interval, 89.30%-99.21%) in the HCV group versus 156 individuals (98.74%; 95.50%-99.85%) in healthy control group (P = .23). No significant differences were found between the 2 groups in rates of nonresponse, low response, normal response, and high response after hepatitis B vaccination (all P > .05). The details of the anti-HBs response are shown in Table 2 .
Factors Associated With Antibody Response in the HCV Group
The rates of nonresponse and low response were 5.71%, 12.90%, and 38.46% in patients with normal-weight, overweight, and obese patients, respectively. Patients with higher BMI had higher rates of nonresponse or low response (P = .01). Notably, sex, age, smoking, alcohol consumption, or liver disease status was not associated with the response (all P > .05). Our study also showed that abnormal values for ALT, AST, serum bilirubin, albumin, and prothrombin time did not decrease the response of the vaccine. There was still no difference between RNA viral quantification and the rate of nonresponse or low response (P = .87) ( Table 3) .
CMI Response Analysis
Of all 80 subjects who underwent CMI assay, 37 subjects were in the HCV group and 43 in the healthy control group. As for the IFN-γ SFCs stimulated by S 28-39 , MHC I and II polypeptide, or HBsAg before or after vaccination, no significant difference was observed between the 2 groups (all P > .05) or after vaccination in either group (all P > .05). There was no significant difference between the 2 groups in IL-2, IL-4, or IL-5 SFC counts with HBsAg stimulation before vaccination (all P > .05). IL-2, IL-4, and IL-5 SFC counts increased significantly after vaccination compared with before vaccination in both the HCV and healthy control groups (all P < .05). Although the mean and median IL-2, IL-4, or IL-5 SFC counts were higher in the control group than in the HCV group, there were no significant differences between the 2 groups (all P > .05) (Figure 2 ). IL-6 SFCs were too numerous in each group before or after vaccination, exceeded the counting range of the SFC counter. Thus, IL-6 SFCs were not counted.
Correlation Between Cytokine and Antibody Titers
The enzyme-linked immunospot SFCs of IL-2, IL-4, and IL-5 were counted (Supplementary Tables S1-S3 ). IL-2 SFC counts varied by anti-HBs level, and with the elevation in antibody titers, IL-2 SFC counts increased gradually (χ 2 = 10.98; P < .05). However, IL-4 or IL-5 SFC counts showed no significant difference between different anti-HBs levels (P > .05). IL-2 or IL-5 SFC counts were positively correlated with anti-HBs titer (coefficients, 0.34 and 0.29, respectively; P < .05), but the IL-4 SFC counts showed no significant correlation with anti-HBs titer (P = .07). 
Safety
Overall, 4 of 79 subjects (5.06%) in the HCV group and 16 of 158 (10.13%) in the healthy control group experienced ≥1 solicited adverse event. No significant differences were found in the incidence of adverse events between the 2 groups (P = .19). Injection site pain was reported by 1 patient in the HCV group. Injection site pain and edema were observed in 1 healthy individual, and injection site pruritus, induration, and edema in another. The most common solicited systemic reaction was fever in both groups, which was reported by 3 of 79 subjects (3.80%) in the HCV group and 11 of 158 (6.96%) in the control group. In addition, fatigue, diarrhea, and recurrence of epilepsy were observed in 1 healthy individual each. No severe adverse effect was reported in either group.
DISCUSSION
To our knowledge, the present study is the first clinical trial evaluating the immunogenicity and safety of hepatitis B vaccine among patients with chronic hepatitis C in China. We observed a satisfactory antibody response among patients with chronic hepatitis C, similar to that in the healthy control group. The results were in agreement with the past 4 studies [13, 16, 26, 27] but were opposite the results in the other 7 studies (Supplementary Table S4 ) [14, 15, [28] [29] [30] [31] [32] . In 4 of the latter 7 studies, some patients with hepatitis C patients had serious liver damage or developed cirrhosis [14, 15, 28, 30] . In our study, only 1 of 79 patients had cirrhosis, and the others had mild liver damaged or were HCV carriers without liver damage. The degree of liver damage may account for the different responses to hepatitis B vaccine in different studies. So far, the immunologic basis for nonresponse to hepatitis B vaccine among patients with HCV infection has not been thoroughly studied. One study found that programmed death-1 (PD-1) signaling as a costimulatory signal might be involved in impairing CD4 + T-cell responses to hepatitis B vaccine in subjects with HCV infection [33] . Further studies were suggested to document the association between antibody responses after hepatitis B vaccination and the severity of liver damage.
Other than BMI, no demographic or biochemical factors were found to be associates with the response to hepatitis B vaccine among patients with chronic hepatitis C, findings consistent with those of 2 other trials [28, 32] . However, no significant difference was found between different BMI groups among healthy controls for either the geometric mean concentration of anti-HBs or the seroconversion rate. The different effects of BMI on hepatitis B vaccine response in the 2 groups may be due to chance. It has been demonstrated that antibody response to hepatitis B vaccine decreased with increasing age [34, 35] , but we did not observe this association for most subjects in our study aged ≥40 years.
In agreement with other studies we observed that RNA viral quantification was not associated with antibody response to hepatitis B vaccination [15, 28] . Controversial results, however, have been reported, showing that viral load seemed to negatively influence the response to hepatitis B vaccine [29] . Patients with diabetes had lower antibody response to hepatitis B vaccine than the healthy population, according to some studies [36] . The present study included only 1 patient and 2 controls with diabetes. We did not explore the effect of diabetes on hepatitis B vaccine response because the number of affected subjects was too limited and would not cause significant impact on the results of the study.
Our study also found that IL-2, IL-4, and IL-5 SFC counts increased significantly between the 2 groups after vaccination. The IFN-γ SFC counts were relatively low, a finding that may characterize immune responses induced by hepatitis B vaccine expressed by S. cerevisia. IL-2 responses in healthy control group were consistent with previously reported findings [23] . We also observed high IL-6 responses in both the HCV and healthy control groups, which may explain the consistent antibody levels in the 2 groups.
B and T cells were all involved in the antibody response to hepatitis B vaccine, and HBsAg-specific CMI was significantly lower in nonresponders [22] . Our research results demonstrated that anti-HBs immunoglobulin G and specific CMI could not be induced in mice with T-cell deficiency (unpublished findings), proving that T cells played roles in antibody production. Our study also found that IL-2 or IL-5 SFC counts and anti-HBs tilters had a significant positive correlation, which suggests that individuals with antibody ≥100 mIU/mL may be prone to develop a satisfactory cytokine response. Abbreviations: Anti-HBs, antibody to hepatitis B surface antigen; CI, confidence interval; GMC, geometric mean concentration; HCV, hepatitis C virus.
a P values obtained using conditioned logistic regression analysis. Our results suggest that the standard 20-μg intramuscular 3-dose schedule can induce satisfactory response among HCV carriers or patients with mild liver damage. Indeed, this finding implies that hepatitis B vaccine should be recommended to individuals with HCV infection detected at an early stage of liver disease. In fact, in the majority of individuals, HCV infection was detected accidentally at premarital, prepregnancy, preoperative, or volunteer blood donation examination in China. Most of these individuals were HCV carriers or patients with mild liver damage. Therefore, hepatitis B vaccine should be recommended as a priority to individuals with HCV infection in these sites.
In the present study, both groups reported a lower incidence of local reactions at the injection site and similar incidences of systemic reactions. Overall, the incidence of reactions in our study was lower than other studies [26, 28, 32] . One possible reason was that the participants in this study were all peasants with poor health consciousness or a high threshold of tolerance for minor discomfort. They were not aware of slight discomfort and failed to report it. Another reason may be our small sample size. Consistent with the results of other studies [14, 16, 26] , we did not observe any severe adverse events, which suggests that hepatitis B vaccination may be safe in patients with chronic hepatitis C infection.
Strict quality control measures were performed in our study. First, this trial was strictly controlled. Questionnaire surveys, sample collection, and assays were performed the same way in both groups. In addition, subjects with induced anti-HBs ≥100 mIU/mL 1 month after the first vaccine dose were deemed to have a history of HBV infection or hepatitis B vaccination and were excluded from the study [21] . Furthermore, all samples were commissioned to a third-party for blind testing. Finally, to check the accuracy of assays and exclude detection bias, 20 samples from each group 1 month after the last dose were selected randomly and measured in 2 test organizations with the same methods and different test agents. The results were comparable (d = 1.07 mIU/mL for the HCV group and 1.11 mIU/mL for the healthy control group) (Supplementary Table S5) .
Our study has some limitations. First, most patients were noncirrhotic, so we could not evaluate the effect of cirrhosis on immunogenicity of the hepatitis B vaccine. Second, because the overall sample was small, some comparisons were limited by the small size of certain subgroups. Third, most subjects in our study were aged ≥40 years, and differences in antibody response between infected and control groups may be weakened in this age group. Fourth, the potential impacts of hepatitis B vaccination on blood biochemical parameters related to liver function were not observed among patients with chronic hepatitis C infection. We observed no adverse events associated with clinical manifestations induced by liver dysfunction, neither by self-report or active inquiry.
In conclusion, this study provided preliminary evidence of the good immunogenicity and safety of hepatitis B vaccine in patients with chronic hepatitis C in China. Further studies with large samples should be conducted in the future.
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